FY2025 · ended Dec 31, 2025 · Revenue $2.88M, -43.1% YoY · Filed May 29, 2026
Stemtech Corporation (STEK) files with the SEC under industry code 5122, Wholesale-Drugs, Proprietaries & Druggists' Sundries. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $2.9 million and a net loss of $4.0 million. Free cash flow was -$483,583. As of Jun 30, 2026 it held $246,772 in cash and investments and $4.4 million in total debt.
Revenue (TTM)
$2.40M
-38.6% vs year-ago TTM
Net income (TTM)
$-3.75M
-12.9% vs year-ago TTM
Operating cash flow (TTM)
$-328,755
+84.2% vs year-ago TTM
Free cash flow (TTM)
$-328,755
+84.2% vs year-ago TTM
EPS (TTM)
$-0.00
+81.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
2.07B
+1351.8% vs prior year
Net cash
$-4.15M
as of Jun 30, 2026
Operating margin
-97.0%
FY 2026
Company profile
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (SIC 5122)
- Listed as
- STEK (OTC)
- Fiscal year ends
- December 31
- Headquarters
- Naples, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1511820
- Former names
- Globe Net Wireless Corp. (until Sep 21, 2021)
Other Wholesale-Drugs, Proprietaries & Druggists' Sundries companies
- Mckesson Corp MCK
- Cencora, Inc. COR
- Cardinal Health Inc CAH
- Herbalife Ltd. HLF
- Nu Skin Enterprises, Inc. NUS
- EnerSyn Global Inc. ESYN
- Cosmos Health Inc. COSM
- DataMeds AI, Inc. MEDS
All 11 Wholesale-Drugs, Proprietaries & Druggists' Sundries companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.9M | $5.1M | $4.9M | $4.6M | $4.3M |
| Operating income | -$2.7M | -$2.4M | -$4.2M | -$5.0M | -$3.2M |
| Net income | -$4.0M | -$3.8M | -$5.4M | -$8.5M | -$7.1M |
| Diluted EPS | -$0.02 | -$0.03 | -$0.07 | -$0.19 | -$0.20 |
| Operating cash flow | -$483,583 | -$601,198 | -$2.0M | -$1.2M | -$1.9M |
| Free cash flow | -$483,583 | -$601,198 | — | — | — |
| Total assets | $3.1M | $3.8M | $3.7M | $4.3M | $5.7M |
| Total liabilities | $10.6M | $8.7M | $6.5M | $7.4M | $9.7M |
| Stockholders' equity | -$7.0M | -$4.5M | -$2.0M | -$2.4M | — |
| Cash and investments | $238,245 | $255,298 | $114,166 | $132,487 | $828,206 |
| Total debt | $4.2M | $3.8M | $3.6M | $142,133 | $174,810 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | Jun 22, 2026 | Mar 31, 2026 |
| 10-K | Annual report | May 29, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Nov 19, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 19, 2025 | Jun 30, 2025 |
| 10-Q | Quarterly report | Jul 17, 2025 | Mar 31, 2025 |
All 159 Stemtech Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.